Karen Sweiss1,2, Bhaskar Vemu1, Craig C Hofmeister3, Eric Wenzler1, Gregory Sampang Calip2,4, John P Galvin2,5, Nadim Mahmud2,5, Damiano Rondelli2,5, Jeremy James Johnson1,2, Pritesh Patel2,5. 1. Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA. 2. Cancer Center, University of Illinois, Chicago, IL, USA. 3. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. 4. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, USA. 5. Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA.
Abstract
AIMS: High dose melphalan (HDM) and autologous stem cell transplant (ASCT) is standard of care for multiple myeloma (MM), but there is significant variability in melphalan exposure (area under the plasma drug concentration-time curve, AUC) when using body surface area-based dosing. Our aim was to establish a method of pharmacokinetic (PK) testing for real-time melphalan dose adjustments. METHODS: We performed a prospective PK study of melphalan 140 or 200 mg/m2 in MM patients undergoing ASCT. Twenty MM patients were administered HDM on days -2 and - 1, with PK sampling at 8-10 time points. PK testing was performed on day -2 in all patients, and on day -1 in 5 patients. RESULTS: Less than 20% interpatient variation in the day -2 and - 1 AUC was observed. The day -2 range in AUC (4.95-11.28 mg h/L) confirmed significant interpatient variability. The hypothetical total dose ranged from 133-302 mg/m2 to achieve the total median AUC. A 4-time point AUC (0, 30, 150 and 240 min) highly correlated with the AUC from the 8-time point schedule. A higher AUC correlated with increased risk of febrile neutropenia (P = .05). CONCLUSION: Here we outline the methods to establish novel melphalan dosing using PK testing in MM patients undergoing ASCT to target a desired melphalan AUC.
AIMS: High dose melphalan (HDM) and autologous stem cell transplant (ASCT) is standard of care for multiple myeloma (MM), but there is significant variability in melphalan exposure (area under the plasma drug concentration-time curve, AUC) when using body surface area-based dosing. Our aim was to establish a method of pharmacokinetic (PK) testing for real-time melphalan dose adjustments. METHODS: We performed a prospective PK study of melphalan 140 or 200 mg/m2 in MMpatients undergoing ASCT. Twenty MMpatients were administered HDM on days -2 and - 1, with PK sampling at 8-10 time points. PK testing was performed on day -2 in all patients, and on day -1 in 5 patients. RESULTS: Less than 20% interpatient variation in the day -2 and - 1 AUC was observed. The day -2 range in AUC (4.95-11.28 mg h/L) confirmed significant interpatient variability. The hypothetical total dose ranged from 133-302 mg/m2 to achieve the total median AUC. A 4-time point AUC (0, 30, 150 and 240 min) highly correlated with the AUC from the 8-time point schedule. A higher AUC correlated with increased risk of febrile neutropenia (P = .05). CONCLUSION: Here we outline the methods to establish novel melphalan dosing using PK testing in MMpatients undergoing ASCT to target a desired melphalan AUC.
Authors: Christine Chen; David Siegel; Martin Gutierrez; Meagan Jacoby; Craig C Hofmeister; Nashat Gabrail; Rachid Baz; Morten Mau-Sorensen; Jesus G Berdeja; Michael Savona; Lynn Savoie; Suzanne Trudel; Nuchanan Areethamsirikul; T J Unger; Tami Rashal; Tim Hanke; Michael Kauffman; Sharon Shacham; Donna Reece Journal: Blood Date: 2017-12-04 Impact factor: 22.113
Authors: Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau Journal: N Engl J Med Date: 2017-04-06 Impact factor: 91.245
Authors: Parameswaran Hari; Donna E Reece; Jasleen Randhawa; Neal Flomenberg; Dianna S Howard; Ashrof Z Badros; Aaron P Rapoport; Barry R Meisenberg; Joanne Filicko-Ohara; Gordon L Phillips; David H Vesole Journal: Bone Marrow Transplant Date: 2018-06-15 Impact factor: 5.483
Authors: A Kühne; O Sezer; U Heider; I Meineke; S Muhlke; W Niere; T Overbeck; K Hohloch; L Trümper; J Brockmöller; R Kaiser Journal: Clin Pharmacol Ther Date: 2007-10-03 Impact factor: 6.875
Authors: G Tricot; D S Alberts; C Johnson; D J Roe; R T Dorr; D Bracy; D H Vesole; S Jagannath; R Meyers; B Barlogie Journal: Clin Cancer Res Date: 1996-06 Impact factor: 12.531
Authors: Jennifer L Giglia; Marquitta J White; Andrew J Hart; Juan J Toro; César O Freytes; Cherish C Holt; Ying Cai; Scott M Williams; Stephen J Brandt Journal: Biol Blood Marrow Transplant Date: 2014-04-04 Impact factor: 5.742
Authors: Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau Journal: Lancet Oncol Date: 2016-08 Impact factor: 41.316
Authors: Christa Ellen Nath; Andrew Grigg; Sebastian P A Rosser; Jane Estell; Elizabeth Newman; Campbell Tiley; Sundra Ramanathan; Shir Jing Ho; Stephen Larsen; John Gibson; Peter Presgrave; Peter John Shaw; Judith Trotman Journal: Eur J Clin Pharmacol Date: 2022-10-07 Impact factor: 3.064